[1] Cheah M C C, Crane H, George J. Global prevalence, metabolic characteristics, and outcomes of lean-MAFLD: a systematic review and meta-analysis[J]. Hepatol Int, 2025, 19(3):607-618.
[2] Cheng H N, Daniel Q H, Mindie H N. Nonalcoholic fatty liver disease versus metabolic-associated fatty liver disease: prevalence, outcomes and implications of a change in name[J]. Clin Mol Hepatol, 2022, 28(4):790-801.
[3] Alexander H Y, Monica A T, Federica T, et al. Prevalence of steatotic liver disease, advanced fibrosis and cirrhosis among community-dwelling overweight and obese individuals in the USA[J]. Gut, 2024, 73(12):2045-2053.
[4] Veeral A, Sandra C, Kaleb T, et al. A prospective study on the prevalence of NAFLD, advanced fibrosis, cirrhosis and hepatocellular carcinoma in people with type 2 diabetes[J]. J Hepatol, 2023, 78(3):471-478.
[5] Marti-Aguado D, Calleja J L, Vilar-Gomez E, et al. Low-to-moderate alcohol consumption is associated with increased fibrosis in individuals with metabolic dysfunction-associated steatotic liver disease[J]. J Hepatol, 2024, 81(6):930-940.
[6] Luis A D, Juan P A, Alexandre L, et al. The intersection between alcohol-related liver disease and nonalcoholic fatty liver disease[J]. Nat Rev Gastroenterol Hepatol,2023,20(12):764-783.
[7] David M A, Ana C S, Ramon B, et al. Cigarette smoking and liver diseases[J]. J Hepatol, 2022, 77(1):191-205.
[8] Alessandro C, Mahnoosh O, Oveis J, et al. Interaction between estrogen receptor-α and PNPLA3 p.I148M variant drives fatty liver disease susceptibility in women[J]. Nat Med, 2023, 29(10):2643-2655.
[9] Stephen A H, Pierre B, Cynthia D G, et al. A phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis[J]. N Engl J Med, 2024, 390(6):497-509.
[10] Alina M A, Ray K, Patrizia C, et al. Population perspectives on benefits and harms of screening for metabolic dysfunction-associated steatotic liver disease[J]. Hepatology, 2026, 83(2):362-373.
[11] EASL, EASD, EASO, EASL. EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD)[J]. J Hepatol, 2024, 81(3):492-542.
[12] Chul-Min L, Eileen L Y, Atsushi N, et al. A reappraisal of the diagnostic performance of B-mode ultrasonography for mild liver steatosis[J]. Am J Gastroenterol, 2023, 118(5):840-847.
[13] Cyrielle C, Mosab H A, Phirum N, et al. Optimal threshold of controlled attenuation parameter with MRI-PDFF as the gold standard for the detection of hepatic steatosis[J]. Hepatology, 2018, 67(4):1348-1359.
[14] Philip N N, Magali S, Jonathan J D, et al. FibroScan-AST (FAST) score for the non-invasive identification of patients with non-alcoholic steatohepatitis with significant activity and fibrosis: a prospective derivation and global validation study[J]. Lancet Gastroenterol Hepatol, 2020, 5(4):362-373.
[15] Mazen N, Emily T, Jeffrey A G, et al. MRI-based (MAST) score accurately identifies patients with NASH and significant fibrosis[J]. J Hepatol, 2022, 76(4):781-787.
[16] Stuart M, Stephen F S, Elsbeth H, et al. Simple non-invasive fibrosis scoring systems can reliably exclude advanced fibrosis in patients with non-alcoholic fatty liver disease[J]. Gut, 2010, 59(9):1265-1269.
[17] Jia-Xu L, Javier A, Hao N, et al. An individual patient data meta-analysis to determine cut-offs for and confounders of NAFLD-fibrosis staging with magnetic resonance elastography[J]. J Hepatol, 2023, 79(3):592-604.
[18] Zobair M Y, Kathleen E C, Joseph K L, et al. AGA Clinical Practice Update on lifestyle modification using diet and exercise to achieve weight loss in the management of nonalcoholic fatty liver disease: expert review[J]. Gastroenterology, 2021, 160(3):912-918.
[19] Estruch R. Primary prevention of cardiovascular disease with a mediterranean diet supplemented with extra-virgin olive oil or nuts[J]. N Engl J Med, 2018, 379(14):1388.
[20] Chanthawat P, Kiera R, Sajesh K V, et al. Intermittent fasting and obesity-related health outcomes: an umbrella review of meta-analyses of randomized clinical trials[J]. JAMA Netw Open, 2021, 4(12):e2139558.
[21] Guo L X, Xi Y, Jin W B, et al. A 5∶2 intermittent fasting meal replacement diet and glycemic control for adults with diabetes: the EARLY randomized clinical trial[J]. JAMA Netw Open, 2024, 7(6):e2416786.
[22] Sun X Y, Li F, Yan H M, et al. Intermittent compared with continuous calorie restriction for treatment of metabolic dysfunction-associated steatotic liver disease: a randomized clinical trial[J]. Am J Clin Nutr, 2025, 121(1):158-166.
[23] Naparat S, Supawan B. Effect of intermittent fasting 16∶8 and 14∶10 compared with control-group on weight reduction and metabolic outcomes in obesity with type 2 diabetes patients: a randomized controlled trial[J]. J Diabetes Investig, 2024, 15(9):1297-1305.
[24] Dimitrios A K, Nerys M A, Kate E T, et al. Association of weight loss interventions with changes in biomarkers of nonalcoholic fatty liver disease: a systematic review and meta-analysis[J]. JAMA Intern Med, 2019, 179(9):1262-1271.
[25] DiBattista J V, Lok A S, Chen V L, et al. Long-term weight changes are associated with initial weight changes after nonalcoholic fatty liver disease diagnosis[J]. Hepatol Commun, 2023, 7(3):e0044.
[26] Keating S E, Sabag A, Hallsworth K, et al. Exercise in the management of metabolic-associated fatty liver disease (MAFLD) in adults: A position statement from exercise and sport science Australia[J]. Sports Med, 2023, 53(12):2347-2371.
[27] Harrison S A, Taub R, Neff G W, et al. Resmetirom for nonalcoholic fatty liver disease: a randomized, double-blind, placebo-controlled phase 3 trial[J]. Nat Med, 2023, 29(11):2919-2928.
[28] Karim G, Bansal MB. Resmetirom: an orally administered, small-molecule, liver-directed, β-selective THR agonist for the treatment of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis[J]. touchREV Endocrinol, 2023, 19(1):60-70.
[29] Newsome P N, Buchholtz K, Cusi K, et al. A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis[J]. N Engl J Med, 2021, 384(12):1113-1124.
[30] Zhou X D, Kim S U, Yip T C, et al. Long-term liver-related outcomes and liver stiffness progression of statin usage in steatotic liver disease[J]. Gut, 2024, 73(11):1883-1892.
[31] Simon T G, Wilechansky R M, Stoyanova S, et al. Aspirin for metabolic dysfunction-associated steatotic liver disease without cirrhosis: a randomized clinical trial[J]. JAMA, 2024, 331(11):920-929.
[32] Mohamed I E, You L, John F P, et al. Association of bariatric surgery with cardiovascular outcomes in adults with severe obesity and nonalcoholic fatty liver disease[J]. JAMA Netw Open, 2022, 5(10):e2235003. |
